NFE2L2 and renal carcinoma: These findings indicate that overexpression of DPP9 might protect renal cancer cells from ferroptosis through the binding of DPP9 to KEAP1 and the upregulation of NRF2-controlled genes and that the inhibition of KEAP1-DPP9 interaction might be a therapeutic strategy to overcome this effect in renal cancer [157].